We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Part of Valneva
Clinical Trials
56
16 active
Approvals
6
Total approvals
Agencies
3
Regulatory bodies
Founded
N/A
Active, not recruiting
14
25.0%
Completed
36
64.3%
Enrolling By Invitation
2
3.6%
Withdrawn
4
7.1%
EMA
European Medicines Agency
CANADA
Health Canada
CIMA_AEMPS
Spanish Agency for Medicines and Medical Devices
- A phase 3b trial of VLA1553 showed that chikungunya virus-neutralizing antibodies persisted for up to two years post-vaccination. - Seroprotection rates remained high, at or above 97% at one year and 96.8% at two years, across all age groups studied. - The study found no long-term safety concerns related to VLA1553, with serious adverse events deemed unrelated to the vaccine. - These findings support VLA1553's potential for active immunization in individuals living in or traveling to chikungunya-endemic areas.
